Research Article

Expectancy of Stress-Reducing Aromatherapy Effect and Performance on a Stress-Sensitive Cognitive Task

Irina Chamine1 and Barry S. Oken2

1Department of Behavioral Neuroscience, Oregon Health & Science University, Mail Code CR120, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA
2Departments of Neurology, Behavioral Neuroscience and Biomedical Engineering, Oregon Health & Science University, Mail Code CR120, 3181 SW Sam Jackson Park Road, Portland, OR 97239, USA

Correspondence should be addressed to Irina Chamine; fonareva@ohsu.edu

Received 3 November 2014; Accepted 23 December 2014

Academic Editor: Karin Meissner

Copyright © 2015 I. Chamine and B. S. Oken. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. Stress-reducing therapies help maintain cognitive performance during stress. Aromatherapy is popular for stress reduction, but its effectiveness and mechanism are unclear. This study examined stress-reducing effects of aromatherapy on cognitive function using the go/no-go (GNG) task performance and event-related potentials (ERP) components sensitive to stress. The study also assessed the importance of expectancy in aromatherapy actions.

Methods. 81 adults were randomized to 3 aroma groups (active experimental, detectable, and undetectable placebo) and 2 prime subgroups (prime suggesting stress-reducing aroma effects or no-prime). GNG performance, ERPs, subjective expected aroma effects, and stress ratings were assessed at baseline and poststress.

Results. No specific aroma effects on stress or cognition were observed. However, regardless of experienced aroma, people receiving a prime displayed faster poststress median reaction times than those receiving no prime. A significant interaction for N200 amplitude indicated divergent ERP patterns between baseline and poststress for go and no-go stimuli depending on the prime subgroup. Furthermore, trends for beneficial prime effects were shown on poststress no-go N200/P300 latencies and N200 amplitude.

Conclusion. While there were no aroma-specific effects on stress or cognition, these results highlight the role of expectancy for poststress response inhibition and attention.

1. Introduction

Stress-management approaches can ameliorate negative consequences of stress on health and cognition [1]. Aromatherapy, therapeutic use of inhaled essential oils, is a popular stress-reducing approach due to low side effects [2, 3], but its effectiveness is questioned. Despite research supporting aromatherapy effectiveness, the existing evidence is not convincing, according to a comprehensive review, due to the poor quality of previous studies [4]. Small samples, mostly subjective outcomes, and inadequate controls and blinding are the major criticisms about previous research [4, 5]. Lack of convincing evidence for aromatherapy actions is also linked to insufficient understanding of aromatherapy mechanism.

The criticisms raised by the previous reviews were addressed by evaluating stress-reducing properties of lavender (Lavandula angustifolia) essential oil in a more rigorous study. Lavender, popular for relaxation and stress reduction [6], has been previously shown to improve cognition [7] and decrease agitation [8, 9], stress [10–13], and anxiety [14–17]. However, some studies demonstrated no specific lavender effects concluding that the changes after aromatherapy exposure occur solely due to expectancy of improvement [18, 19] and considered aromatherapy an “ineffective treatment but an effective placebo” [20]. To evaluate this idea, the role of expectancy in aromatherapy actions was the focus of our investigation.

As a part of a larger trial assessing aromatherapy effects on physiological and cognitive functions [21], this study was rigorously designed and used objective outcomes, two different controls, and assessors blinded to the groups assignment. Stress-reducing lavender aromatherapy properties
were evaluated by testing lavender effects on performance on a cognitive task subserved by executive function espe-
cially vulnerable to stress [22]. We used a visual go/no-go
(GNG) task, requiring responses to some target stimuli (go
conditions) and withholding responses to other target stimuli
(no-go conditions). Inhibitory control assessed by the GNG
task is a central component of executive function [23] and
can be assessed through event related potentials (ERPs) by
evaluating no-go N200 and P300 [23]. Typically used in
relation to processing salient stimuli mediated by attention,
N200/P300 components during the GNG represent response
inhibition subprocesses vulnerable to acute stress [24]. N200
occurring approximately 200 ms after stimulus onset [25] has
enhanced amplitude after stress [24]. Also, N200 of larger
amplitude and shorter latency distinguishes good inhibitors
from the bad ones [26]. P300 occurring between 250 and
650 ms after stimulus onset relates to stimulus classification
speed and attention resource allocation [27].

In this study, we assessed how aromatherapy exposure
during stress affects poststress GNG performance and ERPs.
We also evaluated how the poststress GNG and ERPs are
influenced by expectancy enhanced by a suggestion of pow-
erful relaxing and stress-reducing properties of the assigned aroma.

2. Methods

2.1. Participants. Eighty-one adults (Mage = 58.2, 79% fe-
males), a subset from a larger trial evaluating stress-
reducing aromatherapy effects (clinical trial ID number
NCT01307748), were recruited from the community through
advertisements. Eligibility criteria were assessed by a phone
interview and included (1) age between 50 and 85 years;
(2) good physical and cognitive health (score ≥ 31 on the
Modified Telephone Interview for Cognitive Status [28]);
(3) score ≥ 9 on the Perceived Stress Scale [29] indicating
presence of stress; (4) no medications affecting CNS or
physiologic measures; (5) healthy olfactory function; and (6)
nonsmoking. The study was approved by the Oregon Health
& Science University Institutional Review Board.

2.2. Procedure. After screening, each participant was ran-
domized to an aroma group (lavender, coconut, or water) and
a prime or no-prime subgroup as described below.

2.2.1. Aroma-Based Groups. Each participant experienced
one aroma during the study. To enhance expectancy and
blinding, participants were told that the purpose of the study
was to understand how different aromas affect the body and
to test effects of several different aromas on stress responses.
The participants were also told that the aromas were diluted
and might not be perceptible but remain effective even with-
out the obvious smell. The aromas tested in the study included
detectable putative stress-reducing, detectable placebo, and
undetectable placebo ones.

Detectable placebo aroma served as a control for the
presence of a pleasant smell without stress-relieving phar-
cologic properties to distinguish the effects arising from
a pleasant smell from those arising from specific pharma-
cologic properties of the essential oil tested. Undetectable
placebo aroma was used as a nonactive control without smell.

For the experimental stress-reducing aroma, a drop of
lavender (Lavandula angustifolia) essential oil (Mountain
Rose Herbs, Eugene, OR) was diluted in 15 mL of grapeseed
carrier oil (Now Foods, Bloomingdale, IL).

For the detectable placebo aroma, a teaspoon of virgin
coconut (Cocos nucifera) base oil (The Ananda Apothecary,
Boulder, CO) was diluted in 15 mL of grapeseed carrier oil
(Now Foods, Bloomingdale, IL) and mixed until solution
appeared clear.

For the undetectable placebo aroma, distilled water was
used giving the appearance of essential oil without producing
odor or stress-reducing effects.

2.2.2. Aroma Administration. During the visit, three drops of
the aroma solution were placed on a 5 × 5 mm cotton pad.
The pad attached by transparent odor-free tape came to the
midpoint between the participant’s nose and upper lip and
remained attached until the study completion.

2.2.3. Prime-Based Subgroups. In addition to aroma group,
each participant was randomized into a prime subgroup to
assess expectancy effects, with half of the participants in each
aroma group receiving a prime and the rest receiving no
prime.

Participants in prime subgroup, just prior to aroma expo-
sure, received a card reading: “You are about to experience a
powerful relaxing and stress-reducing aroma. To experience
it best, please close your eyes and inhale the aroma deeply.
You may or may not perceive this aroma. This aroma is known
to provide a profound relief from stress whether or not people
are able to perceive it.”

Participants in no-prime subgroup received a card read-
ing: “You are about to experience an aroma that may or may
not help reduce your stress level. Please close your eyes and
inhale the aroma deeply. You may or may not perceive this
aroma. Aromatherapy can be effective whether or not people
are able to perceive aromas.”

All randomizations were completed by nonblinded
researchers using a computerized adaptive randomization
procedure [30] aimed at balancing aroma groups on distri-
butions of age, gender, and stress score obtained at screening.
Nonblinded researchers also performed debriefings.

2.2.4. Blinding. All study visits were conducted by an assessor
blinded to the participants’ aroma and prime assignment. To
avoid perceiving odors, disposable active carbon nose filters
(Breathe-Ezy Nasal Filters, Henderson, NV) were used.

2.3. Laboratory Visit. All visits started between 12 pm and
12:30 pm to minimize circadian effects.

During the visit, participants signed the consent form
and confirmed their eligibility by screening for general
anosmia with a Quick Smell Identification Test (Sensonics
Inc., Haddon Heights, NJ) [31]. Next, participants were fitted
for ERP recording as described below. After a 30–40 minute
adaptation period that allowed participants to get used to the laboratory setting, the participants started the study procedures involving a baseline assessment, stress battery, and poststress assessment (Table 1). Participants completed self-report and cognitive measures at baseline. Then each participant received a card with or without the prime and began inhaling the assigned aroma. Five minutes afterwards, participants underwent a stress battery followed by the poststress assessment similar to the baseline assessment. The visit took 4 hours. After completing procedures, the participants were debriefed and reimbursed $10.00 per hour.

2.4. Stress Battery. The stress battery consisted of emotional, physical, and mental stressor. Several stressors of different types were used to ensure that participants are stressed by some or all of the presented stressors. The stressors used in the study were chosen because they are tolerated well by human subjects and have been previously demonstrated to be effective in eliciting a stress response and influencing physiologic, endocrine, and cognitive functions that were assessed in the larger trial.

Physical stressor involved the cold pressor task [32] that required keeping a hand in ice-cold water as long as it is tolerable or until 3 minutes elapsed.

Emotional stressor was a 5-minute slideshow of unpleasant images from the International Affective Picture System [33]. Images with valence ≤5 and arousal level ≥5 were presented. To ensure subjects’ attention, participants were instructed to push a button when snake images appeared.

Mental stressor involved the Montreal Imaging Stress Task (MIST) composed of computerized mental arithmetic with a built-in failure algorithm and social evaluative threat component [34]. The MIST software was generously provided by Dr. Jens Pruessner of McGill University.

2.5. Self-Reports. Participants answered questions about demographics and aromatherapy use.

Perceived stress scale (PSS) [29] was used to assess perceived stress level in the previous week. During the screening process, we used the cut-off scores ≥9 because this score represented the mean stress level observed in healthy adults of similar age estimated from previous studies conducted in our laboratory. Recruiting subjects with perceived stress level that is at or above estimated average stress level for the targeted population was done to ensure enrollment of subjects most sensitive to laboratory stressors and thus most likely to benefit from any potential stress-reducing aromatherapy effects.

Expectancy of aromatherapy effect was assessed with visual analog scales (VAS) ranging from 0 to 100 mm. Participants rated expected aromatherapy effect on stress (from decreased to increased stress) and general aromatherapy effect (from overall negative to overall positive effect).

2.6. Stress-Related Measures

2.6.1. Salivary Cortisol. Cortisol samples were collected using Sarstedt Salivettes (Sarstedt AG & Co, Nümbrecht, Germany). Samples were stored in a refrigerator shortly after collection and were centrifuged following the visit completion and stored at −80 F prior to processing by the Oregon Clinical Translational Research Institute Core Laboratory. Saliva samples from each subject at baseline, after stress battery, and during the post stress assessments were run in the same assay batch.

Values for cortisol levels were obtained using a commercially available ELISA kit (Salimetrics, State College, PA 16803).

Subjective stress was rated with a VAS ranging from 0 (no stress) to 100 (extremely stressed).

The positive and negative affect schedule (PANAS) [35] was used to assess positive and negative affect at the time of the assessment. Item for alertness was used as a proxy measure of alertness.

2.7. Cognitive Measures. Simple reaction time (SRT) test was used to evaluate processing speed [36]. Participants pushed a button as quickly as possible when each of twenty-four stimuli (letter “O”) appeared on the computer screen.

Go/no-go (GNG) task included 200 uncued stimuli (80% letter “O” go stimuli, and 20% letter “Q” no-go stimuli) presented for 100 ms on the screen at pseudo-random order with an intertrial interval varying randomly between 1000 and 1300 ms.

Computer tasks were presented using EPrime software version 2 (Psychology Software Tools Inc., Sharpsburg, PA).

2.8. ERPs. EEG was recorded from 32-channel array (10/20 system) using BioSemi Active Two equipment (BioSemi B.V., Amsterdam, Netherlands). The electrooculogram (EOG) was recorded from the electrodes placed above the left external canthus and below the right external canthus. The single-ended signals were converted to differential signals offline with electrodes from right and left hemisphere referenced to the average of both mastoid electrodes. The EEG recordings were monitored to adhere to the offset recording standards of the BioSemi Active Two system. The sampling rate was 1024 Hz.

2.8.1. ERP Processing. All processing was completed offline using BrainVision Analyzer 2.0 (Brain Products GmbH, Gilching, Germany). Average mastoid reference EEG was filtered offline from 0.1 to 70 Hz with a 60 Hz notch filter. Ocular artifacts were removed using independent component analysis [37], and epochs containing other artifacts were removed manually. Segments included 100 ms of activity
prior and 1000 ms of activity following the stimulus onset. Each stimulus type data from correct trials was averaged. N200 was measured relative to baseline as the most negative peak occurring between 170 and 350 ms after stimulus onset. P300 was measured relative to baseline as the most positive peak occurring between 250 and 600 ms after stimulus onset. N200/P300 peak latencies and amplitudes were assessed with BrainVision Analyzer semiautomatic detection function and checked manually.

2.9. Statistics. To assess normality we examined histograms and boxplots and, if needed, used the log, square root, or Box-Cox transforms.

One subject lost GNG data due to computer problems. Some ERP data were lost due to severe artifact contamination (n = 7). The data loss was approximately equal in different groups and subgroups. Differences in sample sizes for different measures reflect these data loss issues.

2.10. Primary Analyses

2.10.1. Behavioral Data. Repeated measures analyses of variance (rmANOVA) with time (baseline versus poststress), aroma (lavender, coconut, and water), and prime subgroup (prime, no-prime) were used to assess effects and interactions in behavioral performance. If groups or subgroups differed on any baseline variable affecting cognitive performance, that variable was used as a covariate in the subsequent analyses.

2.10.2. ERPs. N200/P300 components are typically fronto-centrally maximal for no-go stimuli and centro-parietally maximal for go stimuli [38]. Visual inspection of ERP waveforms suggested the most robust waveforms at Cz; therefore, the analyses were conducted with the Cz data. rmANOVA with time (baseline versus poststress), stimulus type (go versus no-go), aroma (lavender, coconut, and water), and prime subgroup (prime, no-prime) were performed to assess interactions in N200 and P300 amplitude and latency. Additionally, no-go trials were the main focus of the follow-up analyses when an interaction was suggested. To avoid overinflating Type I error due to multiple comparisons, a Bonferroni correction was used to determine significance of each statistical family (aroma effects, prime effects). P values below .0125 were considered significant and those below .05 were considered trends.

2.11. Secondary Analyses. Bivariate Pearson correlations were performed to evaluate relationships among poststress cognitive performance and ERP variables as well as variables associated with expectancy and stress. Due to exploratory nature of the analyses, no multiple comparisons adjustments were used and significance level was at .05.

3. Results

3.1. Baseline Characteristics. The aroma groups and prime subgroups were well matched on most variables (all P’s > .05) as presented in Table 2. However, the participants in no-prime group had more education compared to prime group (P = .04). Therefore, education was a covariate to the behavioral data analyses.

3.2. Stressors Effectiveness. As planned, following the stressor there was a significant increase in subjective stress and decrease in positive affect [39]. Furthermore, changes in stress-related biomarkers (e.g., cortisol) and SRT reaction time indicative of an increased stress were observed [21]. These findings confirm that the stress battery affected participants’ physiological and cognitive functioning.

3.3. Primary Analyses

3.3.1. Behavioral Results. Groups or subgroups did not differ on baseline GNG performance (Tables 3(a) and 3(b)) or ERP measures, all P’s > .05.

Error rates remained stable for all participants regardless of the time point and group/subgroup, all P’s > 0.10. The GNG
Table 3: (a) Comparison of behavioral performances on the go/no-go task by aroma group. (b) Comparison of behavioral performances on the go/no-go task by prime subgroup.

(a)

| Measures          | Lavender Baseline | Poststress | Coconut Baseline | Poststress | Water Baseline | Poststress |
|-------------------|-------------------|------------|------------------|------------|----------------|------------|
| Go (% correct)    | 99.5 (0.9)        | 99.6 (0.8) | 99.4 (0.8)       | 99.3 (1.3) | 99.3 (1.4)    | 99.5 (1.2) |
| No-go (% correct) | 84.5 (12.9)       | 87.5 (11.6)| 78.4 (15.5)      | 81.5 (16.0)| 83.7 (13.5)   | 85.9 (14.4) |
| Median RT, mean (SD) | 366.3 (60.9)     | 346.9 (44.6)| 354.3 (62.2)    | 334.7 (49.0)| 355.2 (67.5) | 342.1 (56.7) |

SD = standard deviation.
Dependent variables: go = performance on go trials, no-go = performance on no-go trials, and median RT = median reaction time.

(b)

| Measures          | Prime Baseline | Poststress | No-prime Baseline | Poststress |
|-------------------|----------------|------------|-------------------|------------|
| Go (% correct)    | 99.2 (1.3)     | 99.3 (1.3) | 99.6 (0.6)        | 99.6 (0.9) |
| No-go (% correct) | 81.9 (13.5)    | 84.3 (14.4)| 82.6 (14.8)       | 85.8 (14.0)|
| Median RT, mean (SD) | 356.6 (59.6)  | 333.2 (48.2)| 360.5 (66.9)    | 349.48 (51.0) |

SD = standard deviation.
Dependent variables: go = performance on go trials, no-go = performance on no-go trials, and median RT = median reaction time.

3.3.2. GNG Median RT for Go Trials. rmANCOVA (covariate: education) indicated shorter median RT to poststress go stimuli, $F(1, 75) = 4.82, P = .03$, a common occurrence due to learning. Further, a time by prime interaction was shown, $F(1, 75) = 4.52, P = .037$. The follow-up analyses showed that, regardless of the aroma present, participants in the prime subgroup had a significant poststress decrease in their median RT beyond general learning effects, $P < .001$, unlike the participants in the no-prime subgroup, $P > .05$. No significant effect of aroma was observed, $P > .05$.

3.4. ERP Results. Figures 1(a) and 1(b) display ERP waveforms for aroma groups and prime subgroups. As expected, distinct GNG effect was observed in P300 amplitude with no-go trials eliciting larger amplitude than go trials, $P < .001$. Similarly, main effects of a stimulus type were shown for N200 and P300 latencies, with no-go trials associated with shorter latencies for both components, $P’s < .01$. Time effects were noted for N200 and P300 amplitudes. Specifically, there were lower N200 amplitudes for poststress go trials compared to baseline, $P = .026$, and reduced difference in P300 amplitude between poststress go and no-go trials compared to baseline. These time effects are likely due to stress and fatigue. These results are consistent with typically observed patterns for these ERP components [26, 40].

3.5. Group/Subgroup Differences. The following analyses assessed ERP differences between aroma groups and prime subgroups with the main focus on no-go stimuli. Generally, decreased latencies and increased amplitudes are indicative of more preserved cognitive function.

3.6. Aroma Effects

3.6.1. N200 Amplitude. A trend for the time × stimulus type × aroma interaction, $F(2, 66) = 3.49, P = .036$, suggested divergent ERP patterns between baseline and poststress for go and no-go stimuli depending on the aroma group. No additional significant interactions or aroma-specific effects were observed in follow-up analyses.

3.7. Prime Effects

3.7.1. N200 Amplitude. A significant time × stimulus type × prime interaction, $F(1, 66) = 7.59, P = .008$, indicated divergent ERP patterns between baseline and poststress for go and no-go stimuli depending on the presence or absence of the prime. Follow-up analyses revealed a trend for a time × prime interaction, $F(1, 68) = 5.11, P = .027$, for no-go trials. Specifically, participants receiving no prime displayed a lower poststress no-go N200 amplitude compared to baseline, $F(1, 33) = 7.68, P = .009$, while participants receiving a prime had no change in poststress no-go N200 amplitude.

3.7.2. N200 Latency. A trend for a three-way interaction for time × stimulus type × prime, $F(2, 66) = 4.77, P = .033$, was observed. Specifically, participants receiving a prime had a trend for a poststress decrease in no-go N200 latency compared to participants in no-prime condition whose poststress latency was increased, $F(1, 68) = 3.03, P = .086$.

3.7.3. P300 Amplitude. No effects were detected.
Figure 1: (a) ERP waveforms for aroma groups, (b) ERP waveforms for prime subgroups. Note: all data presented are from the Cz channel. Positive ERP values are plotted upwards.
on cognitive function. Inhibition indices indicative of protective effects of the prime between prime and no-prime conditions in ERP response to cognitive functions. Furthermore, our data show differences in performance on a cognitive task subserved by higher-order processes. It is likely reflecting negative stress effects. Further, because N200 amplitudes tend to be lower than baseline amplitudes, it is crucial that increases in stress than their nonprimed peers. These results suggest that increasing expectancy is beneficial for GNG performance and can potentially influence general attention and response inhibition processes. Our results agree with previous research showing that performance on tasks where reaction time is crucial can be affected by manipulating expectancy of improvement. For example, increasing expectancy of cognitive improvement by supplying placebo pills labeled as cognitive enhancer benefited performance on several cognitive tasks including the choice reaction time task [36]. Due to simplicity of the go/no-go task in our study, there was no effect of increased speed on accuracy. However, assessing how accuracy of responding is affected by speed is warranted in future studies to clarify underlying mechanisms associated with expectancy for cognitive tasks performance.

3.7.4. P300 Latency. A trend for time × prime interaction, $F(1, 66) = 4.13, P = .046$, was detected. Though participants receiving prime showed a decrease in P300 latency and those receiving no prime showed an increase in P300 latency poststress compared to baseline, these differences were not significant.

3.8. Relationships among GNG, ERP, and Subjective Measures. Table 4 presents the relationships among GNG, ERPs, and subjective measures. As expected, ERP components were related: N200 amplitude was positively related to P300 amplitude, $r = 0.55, P = .005$, and no-go N200 and P300 latencies were also correlated, $r = 0.995, P < .001$. Poststress GNG measures and ERPs were not related.

Baseline expectation of aromatherapy effectiveness was related negatively to poststress no-go P300 amplitude, $r = -0.44, P = .03$, and positively to poststress alertness level, $r = 0.44, P = .02$. Alertness level at poststress assessment related negatively to median RT on GNG go trials, $r = -0.35, P = .08$, but this relationship did not reach conventional significance level.

Subjective stress ratings following stress battery did not correlate with any of the behavioral or ERP variables (data not shown).

### Table 4: Relationships among expectancy, poststress behavioral, and poststress ERP measures.

| Variable                                      | 2      | 3      | 4      | 5      | 6      | 7      | 8  |
|-----------------------------------------------|--------|--------|--------|--------|--------|--------|----|
| (1) GNG med. RT                               | 0.176  | -0.054 | 0.051  | -0.221 | 0.040  | -0.082 | -0.346<sup>T</sup> |
| (2) GNG no-go % errors                        | 1      | -0.166 | -0.309 | -0.132 | -0.278 | 0.304  | 0.151 |
| (3) N200 no-go amplitude                      | 1      | 0.138  | 0.547**| 0.124  | -0.171 | -0.165 |
| (4) N200 no-go latency                        | 1      | -0.192 | 0.995**| -0.288 | -0.110 |
| (5) P300 no-go amplitude                      | 1      | -0.189 | -0.441*| -0.147 |
| (6) P300 no-go latency                        | 1      | -0.291 | -0.106 |
| (7) Expected aroma effect (baseline)          | 1      | 0.443* |
| (8) Alertness level (poststress)              | 1      |        |        |        |        |        |    |

Abbreviations: GNG = go/no-go task, med. RT = median reaction time, SD = standard deviation, and ERP = event-related potential.

<sup>T</sup>.10 < $P$ < .05, * $P$ < .05, and ** $P$ < .01.

4. Discussion

Our study is among the few investigations to date that evaluated effects of aromatherapy using a rigorous design with objective measures, adequate controls, and assessor blinding. In agreement with previous reports indicating expectancy as a part of the mechanism underlying aromatherapy benefits [18, 19], our results point to the importance of expectancy in aromatherapy actions. Specifically, our results showed that regardless of the experienced aroma a suggestion about powerful stress-reducing properties of aromatherapy benefits performance on a cognitive task subserved by higher-order cognitive functions. Furthermore, our data show differences between prime and no-prime conditions in ERP response inhibition indices indicative of protective effects of the prime on cognitive function.

4.1. Behavioral Results. Few errors of commission and omission for GNG in our study indicate that the task was easy for the participants. Easy behavioral tasks often fail to differentiate the performances in different groups or over time when healthy adults are tested [23]. However, when median RT was examined, participants receiving a prime prior to aromatherapy regardless of the type of aroma had a greater decrease in their median RT after exposure to stress than their nonprimed peers. These results suggest that increasing expectancy is beneficial for GNG performance and can potentially influence general attention and response inhibition processes. Our results agree with previous research showing that performance on tasks where reaction time is crucial can be affected by manipulating expectancy of improvement. For example, increasing expectancy of cognitive improvement by supplying placebo pills labeled as cognitive enhancer benefited performance on several cognitive tasks including the choice reaction time task [36]. Due to simplicity of the go/no-go task in our study, there was no effect of increased speed on accuracy. However, assessing how accuracy of responding is affected by speed is warranted in future studies to clarify underlying mechanisms associated with expectancy for cognitive tasks performance.

4.2. ERP Results. We focused primarily on no-go N200 and P300 components representing subprocesses of response inhibition [41, 42] previously shown sensitive to stress [24]. These components are likely suberved by prefrontal areas [43, 44] and anterior cingulate cortex [45–47] considered vulnerable to acute stressors [48]. The study stress battery successfully elicited a stress response in participants as evidenced from a poststress increase in subjective and objective changes [21]. Subtle stress effects were also evident in ERP components for the whole sample. Specifically, poststress amplitudes tended to be lower than baseline amplitudes, likely reflecting negative stress effects. Further, because N200 of decreased amplitudes and longer latencies indicate poorer inhibitory control [26], our results suggest decreased poststress inhibitory control in our sample.

Our data show expectancy effect on N200 components as evidenced by divergent N200 amplitude for go and no-go trials between baseline and poststress depending on...
the prime subgroup. Suggesting powerful stress-reducing aromatherapy effects resulted in a largely preserved N200 profile in prime group compared to decreased poststress N200 amplitude in no-prime group. Because a decrease in N200 amplitude coupled with an increase in N200 latency points to poorer inhibition [26], receiving an expectancy-boosting prime might have prevented the subjects from experiencing decrements in poststress inhibitory control. This notion is further supported by an increase in poststress no-go N200 latency in those not receiving a prime in contrast to a decrease in this component in primed participants. Overall, patterns of no-go N200 indices in our sample indicate that enhancing aromatherapy expectancy regardless of actual aroma helps preserve prestress N200 profiles and benefits cognitive function after stress exposure.

The patterns observed for poststress N200 no-go latency paralleled those for poststress P300 no-go latency: increased P300 latency for no-prime group and decreased P300 latency for the prime group. Differences in P300 latency relate to stimulus classification speed with shorter latencies associated with superior cognitive performance [27]. Therefore, our results suggest that giving an expectancy-boosting prime before stress exposure benefits cognitive function. Some of the interesting ERP results in our study did not reach conventional significance level after adjustment for multiple comparisons; however, we believe the conclusions are valid because of a substantial agreement between behavioral and ERP data. Interestingly, no significant aroma effects on ERP components were revealed potentially due to insufficient statistical power. There were also very few correlations among the study variables. Scarcity of correlations among subjective and objective stress-related variables has been previously reported and explained by complexity and variability of the components involved in producing a stress response. These components are believed to be dissociated due to different dynamics of the underlying systems [49]. Among the general lack of notable associations among cognitive performance, ERP, and subjective variables, it was encouraging seeing that preexisting expectation about aromatherapy positively related to poststress no-go P300 amplitude and poststress alertness level. This indicates that positive expectation of aromatherapy effects stemming from subject’s personal experiences unrelated to experimental manipulation can also provide benefit.

Our results contribute to the growing evidence that verbally induced expectations can influence the therapeutic outcome, with the effects observable in active treatment and placebo groups [50]. More specifically, our findings are in agreement with several other studies reporting enhancement of cognitive performance and other cognition-related tasks, such as reaction times, by expectancies and placebos [36, 51–54]. Though traditionally expectancy and placebo effects have been treated as by-products of interventions and a nuisance in determining the treatment efficacy, more recently these effects have become the focus of investigations. Though not arising from an active procedure or agent, expectancy and placebo effects can produce a variety of effects through psychological and neurobiological mechanisms [55–57]. One of the most important mechanisms studied in relation to placebo responding is expectation or anticipation of therapeutic benefit, which is believed to influence health-related outcomes by reducing anxiety and activating the reward system [50]. Thus, though not arising from “real” treatment, the effects due to expectancy and placebo responses are real and beneficial to people who experience them, and therefore they are worth investigating. Understanding the role of expectancy and enhancing it when appropriate might optimize treatments and lead to better clinical outcomes.

Several limitations are important to mention with regard to our study. First, because our sample included generally healthy people between ages of 50 and 85, it is not clear how the present results generalize to other samples. Second, our sample was limited in size and aroma groups were smaller than subgroups based on the presence of the prime. Therefore, the sample might not have provided sufficient power to detect more subtle effects specific to aromatherapy. Studies assessing effects of expectancy and aromatherapy with larger samples and different populations are warranted. Next, expectancy of aromatherapy effect was assessed only at the baseline and no similar assessments were made after the prime or aroma exposure. Therefore, we cannot definitively state that the effects observed in the study were due to a changed expectancy in response to the prime statement. However, since all participants had the same procedure and the changes in wording of the instructions given prior to aroma exposure were the only difference between the prime and no-prime subgroups, we believe the differential outcome was due to that manipulation aimed at changing expectancy. Nevertheless, not directly assessing the change in expectancy after exposure to the prime is a limitation in our study. Further, the study was introduced as the assessment of different aromas for stress reduction without mentioning any placebo arms, and participants were not assessed at the end of the study on whether they thought they had an active stress-reducing aromatherapy or a placebo treatment. It might be beneficial to include an assessment of blinding success in any future studies. Despite these limitations, we believe our findings are valid and point to importance of expectancy in aromatherapy actions.

5. Conclusions

Overall, while not detecting aromatherapy-specific effect on stress, our study provides the evidence that manipulating expectancy by verbal suggestion of aromatherapy effectiveness might underlie some changes in behavior and brain function after exposure to aromatherapy. Our results indicate that enhancing beliefs in a positive effect of an intervention might be beneficial for performance.

Abbreviations

- EEG: Electroencephalography
- ERP: Event related potentials
- GNG: Go/no-go
- IAPS: The International Affective Picture System
- MIST: The Montreal Imaging Stressor Task
PANAS: The positive and negative affect schedule
PSS: Perceived stress scale
RT: Reaction time
SRT: Simple reaction time
TICS: The modified Telephone Interview for Cognitive Status
VAS: Visual analogue scale.

**Conflict of Interests**

The authors report no conflict of interests associated with this work.

**Acknowledgments**

This work was supported by the National Institutes of Health (T32AT002688 (Irina Chamine), K24AT005121 (Barry S. Oken)), F31AT006647 (Irina Chamine), and P30AG008017 (T32AT002688 (Irina Chamine), K24AT005121 (Barry S. Oken)). The authors thank Elena Goodrich and Barry S. Oken for help with blinding the subjects. They also thank Helane Wahlbeh for help with the study and Andy Fish for administrative support.

**References**

[1] W. S. Kremen, M. E. Lachman, J. C. Pruessner, M. Sliwinski, and R. S. Wilson, "Mechanisms of age-related cognitive change and targets for intervention: social interactions and stress," *Journal of Gerontology Series A: Biological Sciences and Medical Sciences*, vol. 67, no. 7, pp. 760–765, 2012.

[2] A. Butje, E. Repede, and M. M. Shattell, "Healing scents: an overview of clinical aromatherapy for emotional distress," *The Journal of Psychosocial Nursing and Mental Health Services*, vol. 46, no. 10, pp. 46–52, 2008.

[3] S. Horowitz, "Aromatherapy: current and emerging applications," *Alternative and Complementary Therapies*, vol. 17, no. 1, pp. 26–31, 2011.

[4] M. S. Lee, J. Choi, P. Posadzki, and E. Ernst, "Aromatherapy for health care: an overview of systematic reviews," *Maturitas*, vol. 71, no. 3, pp. 257–260, 2012.

[5] R. S. Herz, "Aromatherapy facts and fictions: a scientific analysis of olfactory effects on mood, physiology and behavior," *International Journal of Neuroscience*, vol. 119, no. 2, pp. 263–290, 2009.

[6] J. Ilmberger, E. Heuberger, C. Mahrhofner, H. Dessovic, D. Kowarik, and G. Buchbauer, "The influence of essential oils on human attention. I: alertness," *Chemical Senses*, vol. 26, no. 3, pp. 239–245, 2001.

[7] M. A. Diego, N. A. Jones, T. Field et al., "Aromatherapy positively affects mood, EEG patterns of alertness and math computations," *International Journal of Neuroscience*, vol. 96, no. 3–4, pp. 217–224, 1998.

[8] C. Holmes, V. Hopkins, C. Hensford, V. MacLaughlin, D. Wilkinson, and H. Rosenvinge, "Lavender oil as a treatment for agitated behaviour in severe dementia: a placebo controlled study," *International Journal of Geriatric Psychiatry*, vol. 17, no. 4, pp. 305–308, 2002.

[9] P. W.-K. Lin, W.-C. Chan, B. F.-L. Ng, and L. C.-W. Lam, "Efficacy of aromatherapy (Lavandula angustifolia) as an intervention for agitated behaviours in Chinese older persons with dementia: a cross-over randomized trial," *International Journal of Geriatric Psychiatry*, vol. 22, no. 5, pp. 405–410, 2007.

[10] T. Atsumi and K. Tonosaki, "Smelling lavender and rosemary increases free radical scavenging activity and decreases cortisol level in saliva," *Psychiatry Research*, vol. 150, no. 1, pp. 89–96, 2007.

[11] C. Sanders, M. Diego, M. Fernandez, T. Field, M. Hernandez-Reif, and A. Roca, "EEG asymmetry responses to lavender and rosemary aromas in adults and infants," *International Journal of Neuroscience*, vol. 112, no. 11, pp. 1305–1320, 2002.

[12] K. Takatsuiji, Y. Sugimoto, S. Ishizaki, Y. Ozaki, E. Matsuyama, and Y. Yamaguchi, "The effects of examination stress on salivary cortisol, immunoglobulin A and chromogranin A in nursing students," *Biomedical Research*, vol. 29, no. 4, pp. 221–224, 2008.

[13] M. Toda and K. Morimoto, "Effect of lavender aroma on salivary endocrinological stress markers," *Archives of Oral Biology*, vol. 53, no. 10, pp. 964–968, 2008.

[14] T. Field, T. Field, C. Cullen et al., "Lavender bath oil reduces stress and crying and enhances sleep in very young infants," *Early Human Development*, vol. 84, no. 6, pp. 399–401, 2008.

[15] M. Kritsidima, T. Newton, and K. Asimakopoulou, "The effects of lavender scent on dental patient anxiety levels: a cluster randomised-controlled trial," *Community Dentistry and Oral Epidemiology*, vol. 38, no. 1, pp. 83–87, 2010.

[16] M. Fujii, R. Hatakeyama, Y. Fukuoka et al., "Lavender aroma therapy for behavioral and psychological symptoms in dementia patients," *Geriatrics and Gerontology International*, vol. 8, no. 2, pp. 136–138, 2008.

[17] N. Motomura, A. Sakurai, and Y. Yotsuya, "Reduction of mental stress with lavender odorant," *Perceptual and Motor Skills*, vol. 93, no. 3, pp. 713–718, 2001.

[18] S. Howard and B. M. Hughes, "Expectancies, not aroma, explain impact of lavender aromatherapy on psychophysiological indices of relaxation in young healthy women," *British Journal of Health Psychology*, vol. 13, no. 4, pp. 603–617, 2008.

[19] J. K. Kiecolt-Glaser, J. E. Graham, W. B. Malarkey, K. Porter, S. Lemeshow, and R. Glaser, "Olfactory influences on mood and autonomic, endocrine, and immune function," *Psychoneuroendocrinology*, vol. 33, no. 3, pp. 328–339, 2008.

[20] S. Bent, "Aromatherapy: ineffective treatment or effective placebo?" *Effective Clinical Practice*, vol. 3, no. 4, pp. 188–190, 2000.

[21] I. Fonareva, *Physiological, cognitive, and expectancy effects of aromatherapy following acute stress*, Ph.D. thesis, Department of Behavioral Neuroscience, 2013.

[22] A. F. T. Arnsten, "Stress signalling pathways that impair prefrontal cortex structure and function," *Nature Reviews Neuroscience*, vol. 10, no. 6, pp. 410–422, 2009.

[23] B.-W. Zhang, L. Zhao, and J. Xu, "Electrophysiological activity underlying inhibitory control processes in late-life depression: a Go/Nogo study," *Neuroscience Letters*, vol. 419, no. 3, pp. 225–230, 2007.

[24] N. A. Ceballos, R. J. Giuliano, N. Y. Y. Wicha, and R. Graham, "Acute stress and event-related potential correlates of attention to alcohol images in Social drinkers," *Journal of Studies on Alcohol and Drugs*, vol. 73, no. 5, pp. 761–771, 2012.

[25] M. M. Schroeder, R. B. Lipton, W. Ritter, B. S. Giesser, and H. G. Vaughan Jr., "Event-related potential correlates of early processing in normal aging," *International Journal of Neuroscience*, vol. 80, no. 1–4, pp. 371–382, 1995.

[26] M. Falkenstein, J. Hoormann, and J. Hohnsbein, "ERP components in Go/Nogo tasks and their relation to inhibition," *Acta Psychologica*, vol. 101, no. 2–3, pp. 267–291, 1999.
[27] J. Polich, “Updating P300: an integrative theory of P3a and P3b,” Clinical Neurophysiology, vol. 118, no. 10, pp. 2128–2148, 2007.

[28] D. S. Knopman, R. O. Roberts, Y. E. Geda et al., “Validation of the telephone interview for cognitive status-modified in subjects with normal cognition, mild cognitive impairment, or dementia,” Neuroepidemiology, vol. 34, no. 1, pp. 34–42, 2010.

[29] S. Cohen, T. Kamarck, and R. Mermelstein, “A global measure of perceived stress,” Journal of Health and Social Behavior, vol. 24, no. 4, pp. 385–396, 1983.

[30] S. J. Pocock and R. Simon, “Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial,” Biometrics, vol. 31, no. 1, pp. 103–115, 1975.

[31] A. H. Jackman and R. L. Doty, “Utility of a three-item smell identification test in detecting olfactory dysfunction,” Laryngoscope, vol. 115, no. 12, pp. 2209–2212, 2005.

[32] W. Lovallo, “The cold pressor test and autonomic function: a review and integration,” Psychophysiology, vol. 12, no. 3, pp. 268–282, 1975.

[33] P. J. Lang, M. M. Bradley, and B. N. Cuthbert, International Affective Picture System (IAPS): Technical Manual and Affective Ratings, The Center for Research in Psychophysiology, University of Florida, Gainesville, Fla, USA, 1999.

[34] K. Dedovic, R. Renwick, N. K. Mahani, V. Engert, S. J. Lupien, and J. C. Pruessner, “The montreal imaging stress task: using functional imaging to investigate the effects of perceiving and processing psychosocial stress in the human brain,” Journal of Psychiatry and Neuroscience, vol. 30, no. 5, pp. 319–325, 2005.

[35] D. Watson, L. A. Clark, and A. Tellegen, “Development and validation of brief measures of positive and negative affect: the PANAS scales,” Journal of Personality and Social Psychology, vol. 54, no. 6, pp. 1063–1070, 1988.

[36] B. S. Oken, K. Flegal, D. Zajdel, S. Kishiyma, M. Haas, and D. Peters, “Expectancy effect: impact of pill administration on cognitive performance in healthy seniors,” Journal of Clinical and Experimental Neuropsychology, vol. 30, no. 1, pp. 7–17, 2008.

[37] T. P. Jung, S. Makeig, C. Humphries et al., “Removing electroencephalographic artifacts by blind source separation,” Psychophysiology, vol. 37, no. 2, pp. 163–178, 2000.

[38] S. J. Johnstone, C. B. Pfeffer, R. J. Barry, A. R. Clarke, and J. L. Smith, “Development of inhibitory processing during the Go/NoGo task,” Journal of Psychophysiology, vol. 19, no. 1, pp. 11–23, 2005.

[39] I. Fonareva, M. I. Demidenko, and B. S. Oken, Assessing Sensitivity of Common Physiological Markers of Stress and Evaluating Their Utility for Different Types of Stressors, American Psychosomatic Society, Miami, Fla, USA, 2013.

[40] P. D. Gajewski and M. Falkenstein, “Effects of task complexity on ERP components in Go/NoGo tasks,” International Journal of Psychophysiology, vol. 87, no. 3, pp. 273–278, 2013.

[41] M. Eimer, “Effects of attention and stimulus probability on ERPs in a Go/NoGo task,” Biological Psychology, vol. 35, no. 2, pp. 123–138, 1993.

[42] C. Schelmyer, C. Konrad, P. Zwichserlood, V. Arolt, M. Falkenstein, and C. Beste, “ERP indices for response inhibition are related to anxiety-related personality traits,” Neuropsychologia, vol. 48, no. 9, pp. 2488–2495, 2010.

[43] R. Kawashima, K. Satoh, H. Itoh et al., “Functional anatomy of GO/NO-GO discrimination and response selection—a PET study in man,” Brain Research, vol. 728, no. 1, pp. 79–89, 1996.

[44] K. Rubia, T. Russell, S. Overmeyer et al., “Mapping motor inhibition: conjunctive brain activations across different versions of go/no-go and stop tasks,” NeuroImage, vol. 13, no. 2, pp. 250–261, 2001.

[45] C. Beste, R. Willemssen, C. Saft, and M. Falkenstein, “Error processing in normal aging and in basal ganglia disorders,” Neuroscience, vol. 159, no. 1, pp. 143–149, 2009.

[46] H. Bokura, S. Yamaguchi, and S. Kobayashi, “Electrophysiological correlates for response inhibition in a Go/NoGo task,” Clinical Neurophysiology, vol. 112, no. 12, pp. 2224–2232, 2001.

[47] M. Falkenstein, “Inhibition, conflict and the Nogo-N2,” Clinical Neurophysiology, vol. 117, no. 8, pp. 1638–1640, 2006.

[48] E. R. de Kloet, “Stress in the brain,” European Journal of Pharmacology, vol. 405, no. 1–3, pp. 187–198, 2000.

[49] J. Campbell and U. Ehler, “Acute psychosocial stress: does the emotional stress response correspond with physiological responses?” Psychoneuroendocrinology, vol. 37, no. 8, pp. 1111–1134, 2012.

[50] F. Benedetti, “Placebo effects: from the neurobiological paradigm to translational implications,” Neuron, vol. 84, no. 3, pp. 623–637, 2014.

[51] C. Anderson and J. A. Horne, “Placebo response to caffeine improves reaction time performance in sleepy people,” Human Psychopharmacology, vol. 23, no. 4, pp. 333–336, 2008.

[52] M. W. Green, M. A. Taylor, N. A. Elliman, and O. Rhodes, “Placebo expectancy effects in the relationship between glucose and cognition,” The British Journal of Nutrition, vol. 86, no. 2, pp. 173–179, 2001.

[53] S. Parker, M. Garry, G. O. Einstein, and M. A. McDaniel, “A sham drug improves a demanding prospective memory task,” Memory, vol. 19, no. 6, pp. 606–612, 2011.

[54] U. W. Weger and S. Loughnan, “Mobilizing unused resources: using the placebo concept to enhance cognitive performance,” Quarterly Journal of Experimental Psychology, vol. 66, no. 1, pp. 23–28, 2013.

[55] F. Benedetti and M. Amanzio, “Mechanisms of the placebo response,” Pulmonary Pharmacology and Therapeutics, vol. 26, no. 5, pp. 520–523, 2013.

[56] K. Meissner, U. Binge, L. Colloca, T. D. Wager, A. Watson, and M. A. Flaten, “The placebo effect: advances from different methodological approaches,” The Journal of Neuroscience, vol. 31, no. 45, pp. 16117–16124, 2011.

[57] B. S. Oken, “Placebo effects: clinical aspects and neurobiology,” Brain, vol. 131, no. 11, pp. 2812–2823, 2008.